April 24, 2020 / 6:25 AM / a month ago

BRIEF-NOXXON Pharma Announces Validation Of NOX-A12 Dose Escalation In Brain Cancer Study

April 24 (Reuters) - NOXXON PHARMA NV:

* NOXXON ANNOUNCES THAT DATA SAFETY MONITORING BOARD VALIDATES NOX-A12 DOSE ESCALATION IN PHASE 1/2 BRAIN CANCER STUDY

* RECRUITMENT OF PATIENTS IN SECOND COHORT HAS BEEN INITIATED Source text for Eikon: Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below